Polypill Treatment Offers High Value in Low-Income, Underserved Population

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 13, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, Jan. 13, 2025 -- Polypill treatment for cardiovascular disease prevention is of high value in a low-income, underserved population, according to a study published online Jan. 8 in JAMA Cardiology.

Ciaran N. Kohli-Lynch, Ph.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues simulated clinical and economic outcomes of the Southern Community Cohort Study (SCCS) Polypill Trial from a health care sector perspective, adopting a time horizon of 10 years. In the base case analysis, polypill treatment was priced at $463 per year. An SCCS Polypill Trial-representative cohort of 100,000 individuals and all trial-eligible non-Hispanic Black adults were analyzed.

The researchers found that polypill treatment was projected to yield a mean of 1,190 additional quality-adjusted life-years (QALYs) compared with usual care in the trial-representative cohort of 100,000 individuals, at a cost of about $10,152,000. The cost of polypill treatment was estimated at $8,560 per QALY gained compared with usual care, and had high value in 99 percent of simulations. Polypill treatment was estimated to be of high value and cost-saving when priced at $559 or less per year and $443 or less per year, respectively. Polypill treatment remained high value in almost all sensitivity analyses. Polypill treatment offered high value in a secondary analysis of 3,602,427 trial-eligible non-Hispanic Black U.S. adults, with an estimated cost of $13,400 per QALY gained.

"In this economic evaluation, using a computer simulation model, we projected that the polypill would be high value in this population if priced based on its component medications ($463 per year) and may reduce income-related health disparities," the authors write.

One author disclosed ties to Boehringer Ingelheim.

Abstract/Full Text

Editor's Note (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords